Immunochemical analysis of HPV L1 capsid protein and p16 protein in liquid-based cytology samples from uterine cervical lesions

Cancer

Volumn 114, Issue 2, 2008, Pages 83-88

  Yoshida, Tomomi ^a   Sano, Takaaki ^a   Kanuma, Tatsuya ^b   Owada, Nobuo ^a   Sakurai, Shinji ^a   Fukuda, Toshio ^a   Nakajima, Takashi ^a  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cervix; Human papilloma virus; Immunostaining; L1 capsid protein; Liquid based cytology (LBC); p16 protein

Indexed keywords

CAPSID PROTEIN; CAPSID PROTEIN L1; PROTEIN ANTIBODY; PROTEIN P16; VIRUS PROTEIN;

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER REGRESSION; CORRELATION ANALYSIS; CYTODIAGNOSIS; CYTOLOGY; DISEASE COURSE; FEMALE; HUMAN; IMMUNOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SQUAMOUS INTRAEPITHELIAL LESION; UTERINE CERVIX; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; UTERINE CERVIX EPITHELIUM; WART VIRUS;

ADULT; AGED; CAPSID PROTEINS; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; ONCOGENE PROTEINS, VIRAL; PROGNOSIS; REMISSION INDUCTION; UTERINE CERVICAL NEOPLASMS;

EID: 43149112818     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23366     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. McMurray HR, Nguyen D, Westbrook TF, McAnce DJ. Biology of human papillomaviruses. Int J Exp Path. 2001;82:15-33.
3. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer. 2006;6:753-763.
4. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006;116:1167-1173.
5. Yoshida T, Fukuda T, Sano T, Kanuma T, Owada N, Nakaj'ima T. Usefulness of liquid-based cytology specimens for immunocytochemical study of p16 expression and human papillomavirus testing: comparative study using simultaneously sampled histology materials. Cancer Cytopathol. 2004;102:100-108.
6. Nakao Y, Yang X, Yokoyama M, et al. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br J Cancer. 1997;75:1410-1416.
7. Khleif SN, Gregori J, Yee CL, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA. 1996;93:4350-4354.
8. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 1989;8:3905-3910.
9. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol. 1989;63:4417-4421.
10. Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikura H, Iwamoto A. Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer. Res. 1991;82:524-531.
11. Saqi A, Pasha TL, McGrath CM, Yu GH, Zhang P, Gupta P. Overexpression of p16INK4A in liquid-based specimens (SurePath) as marker of cervical dysplasia and neoplasia. Diag Cytopathol. 2002;27:365-370.
12. Woodhouse SL, Stastny JF, Styer PE, Kennedy M, Praestgaard AH, Davey DD. Interobserver variability in subclassification of squamous intraepithelial lesions: results of the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 1999;123:1079-1084.
13. Klaes R, Benner A, Friedrich T, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol. 2002;26:1389-1399.
14. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia. Pathol Int. 1998;48:580-585.
15. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol. 1998;153:1741-1748.
16. Melsheimer P, Kaul S, Dobeck S, Bastert G. Immunocytochemical detection of HPV high-risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA. Acta Cytol. 2003;47:124-128.
17. Griesser H, Sander H, Hilfrich R, Moser B, Schenck U. Correlation of immunochemical detection of HPV L1 capsid protein in pap smears with regression of high-risk HPV positive mild/moderate dysplasia. Anal Quant Cytol Histol. 2004;26:241-245.
18. Yildiz IZ, Usubutun A, Firat P, Ayhan A, Kucukali T. Efficiency of immunohistochemical p16 expression and HPV typing in cervical squamous intraepithelial lesion grading and review of the p16 literature. Pathol Res Pract. 2007;203:445-449.
19. Gravitt PE, Burk RD, Lorincz A, et al. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev. 2003;12:477-484.
20. Hagensee ME, Koutsky LA, Lee SK, et al. Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions. J Infect Dis. 2000;181:1234-1239.